CV Sciences Inc logo

CVSI - CV Sciences Inc News Story

$0.16 0.0  0.0%

Last Trade - 02/12/21

Sector
Healthcare
Size
Micro Cap
Market Cap £13.5m
Enterprise Value £13.9m
Revenue £15.6m
Position in Universe 6623rd / 7292

CV Sciences, Inc. Announces PlusCBD™ Brand Refresh and New Product Launches

Tue 6th October, 2020 12:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201006:nGNXjYRV


SAN DIEGO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc.
(https://www.globenewswire.com/Tracker?data=w8R_7aVFQ8GgkB5cdoOEEpzxBzREg3haKxs2z7ssNS__dRdZXz6pSVMtgJ6NLZ6DjU-aGl9aAOqCPey4etg3jsgOJKaoKhNnYlgN_-2yQtBNKTBlHlyhPRj8CQuJ_0PwO-apRwvlszCEEYULV0pKNOrnA2hFAv8HlnNoIWrRhoRJ1dN1EPmauHt7kLspPow5TYiJs-hdSPvehaqpoAc5YjlCpYU2_gEf5TF7QfnwabA=)
(OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or
“we”), a preeminent leader in hemp derived cannabidiol (CBD) products,
today announced a comprehensive refresh of its top selling, flagship
PlusCBD™ branded product line and the launch of 30+ new PlusCBD™ products
over the next 45 days.

The new PlusCBD™ brand is a refinement and modernization that includes new
packaging with a contemporary color palette and a post-modern aesthetic to
relay each product’s value proposition across the product offering. The 30+
new product launch includes eight new, innovative products featuring extra
strength gummies and maximum strength softgels. All new PlusCBD™ branded
products are available on our website at www.cvsciences.com.

The refreshed PlusCBD™ packaging features our new, prominently displayed CV
Sciences logo, transparent QR code labeling linked to lab reports to assure
customers of the unrivaled quality, and the milligrams of CBD per serving on
the label.

The PlusCBD™ brand mission statement is now featured on the packaging:
“Modern life is challenging. Our physical, mental and emotional health is
constantly being tested. CV Sciences provides research based solutions for the
well-being of the planet. Our mission is to improve quality of life through
nature and science – and the results speak for themselves. This is health
transformed.”

“The CV Sciences team is thrilled to introduce our refreshed PlusCBD™
products that will leverage our brand equity as the safest and most trusted
CBD product offering available, all designed to resonate with our existing
customers while attracting new consumers,” said Joseph Dowling, Chief
Executive Officer. “We conducted extensive market research to create a fresh
new look with strong value messaging that will drive long-term brand affinity
with a broad consumer audience focused on health and wellness. Our updated
brand and products position CV Sciences for continued growth and industry
leadership in the hemp derived CBD category.”

The top selling CBD brand on the market, PlusCBD™ showcases the synergistic
benefits of full spectrum hemp extract, which constitutes over 500 compounds,
including CBD, cannabinoids, terpenes, and essential fatty acids. PlusCBD™
is sourced from sustainable, non-GMO U.S. hemp, grown on small farms in
Kentucky, and EU certified hemp cultivated by Dutch farmers with decades of
experience.

As the first company to achieve Generally Recognized as Safe (GRAS) status for
hemp derived CBD, CV Sciences offers the highest quality products by:
* Sourcing hemp extracts from superior quality U.S. and EU grown agricultural
hemp
* Maintaining two third party Good Manufacturing Practice certifications (U.S.
Hemp Authority and Eurofins)
* Batch testing in-house and by 3rd party labs throughout the process to
preserve product integrity
* Investing in hemp derived CBD research, including CV Sciences published
pre-clinical safety studies, multiple published PlusCBD case studies, a
randomized clinical trial using Plus CBD, and published post market safety
assessment of CV Sciences products.
About CV Sciences, Inc.

CV, or Curriculum Vitae, is Latin for “course of life”, and science is the
pursuit of truth. CV Sciences: our name is our mission -- improving quality of
life through nature and science.

CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a
consumer product division focused on manufacturing, marketing and selling
plant-based dietary supplements and CBD products to a range of market sectors;
and a drug development division focused on developing and commercializing
CBD-based novel therapeutics. The Company’s PlusCBD™ products are sold at
more than 6,300 retail locations throughout the U.S. and it is the top-selling
brand of hemp-derived CBD on the market, according to SPINS, the leading
provider of syndicated data and insights for the natural, organic and
specialty products industry.  CV Sciences follows all guidelines for Good
Manufacturing Practices (GMP) and the Company’s products are processed,
produced, and tested throughout the manufacturing process to confirm strict
compliance with company standards and specifications.  With a commitment to
science, PlusCBD™ product benefits in healthy people are supported by human
clinical research data, in addition to three published clinical case studies
available on PubMed.gov
(https://www.globenewswire.com/Tracker?data=oCmrPFnA3R-BdRCIWIEVysZfhNOwiSut5PYwfUYqwDxk8HMPxnrFEvmaxEGmuSpO7RLpoYq_-Emd4fiG6p7BBw5LYSgwEtJS6N9NxZhhalwJP4b0UkDRya24WF48cKI_29sRer8c4dcMepVyHMZwR4GwCyKuL3ONsSoG4dVIJeSmPC_HIUPt5trlvMQiBdMcMsfuc8mHMm-GGH8EaI7RAeInT2BXkoVhQcybpMokJSnp8hmEksZBoRrBG_UMc2iK2-5h1QFsm6pCoSQKu3-tWsVR65QTZZtKPJotr6GBD7XSCvU4m9Hj0-_YTXMOCINRS8Hq2H0mLTATpU6YG_fo3A7gKF3Bhl05H8dTaose998=). 
PlusCBD™ was the first hemp CBD supplement brand to invest in the scientific
evidence necessary to receive self-affirmed Generally Recognized as Safe
(GRAS) status. CV Sciences, Inc. has primary offices and facilities in San
Diego, California.  Additional information is available from OTCMarkets.com
or by visiting www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and
information, as defined within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is
subject to the Safe Harbor created by those sections. This material contains
statements about expected future events and/or financial results that are
forward-looking in nature and subject to risks and uncertainties. Such
forward-looking statements by definition involve risks, uncertainties.

CONTACT INFORMATION:
Investor Contact:
ICR
Scott Van Winkle
617-956-6736
scott.vanwinkle@icrinc.com

Media Contact:
ICR
Cory Ziskind
646-277-1232
cory.ziskind@icrinc.com

A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/c785c75c-ef9a-4e2a-a7e8-8532e9f30b0e

(https://www.globenewswire.com/NewsRoom/AttachmentNg/cda334c6-52de-4df0-b0a2-55a02b8a5d52)
PlusCBD Formulas 
(https://www.globenewswire.com/NewsRoom/AttachmentNg/c785c75c-ef9a-4e2a-a7e8-8532e9f30b0e/en)
PlusCBD Formulas


GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.